Showing results (381-390 of 410) with videos related to

Sort By:
Pageof 41
Journal of the American College of Cardiology|October 1, 2013
Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney diseaseYaling Han, Guoying Zhu, Lixian Han, et al.
European Heart Journal|August 4, 2021
LDL cholesterol levels and in-hospital bleeding in patients on high-intensity antithrombotic therapy: findings from the CCC-ACS projectQing Yang, Dongdong Sun, Chongzhe Pei, et al.
Nature Genetics|May 24, 2016
Pancreatic cancer risk variant in LINC00673 creates a miR-1231 binding site and interferes with PTPN11 degradationJian Zheng, Xudong Huang, Wen Tan, et al.
The Lancet. Diabetes & Endocrinology|November 13, 2022
Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trialSilvio E Inzucchi, Brian L Claggett, Muthiah Vaduganathan, et al.
Nature Communications|May 27, 2017
Genomic analysis of oesophageal squamous-cell carcinoma identifies alcohol drinking-related mutation signature and genomic alterationsJiang Chang, Wenle Tan, Zhiqiang Ling, et al.
Thrombosis and Haemostasis|December 11, 2019
Individual Patient Data Pooled Analysis of Randomized Trials of Bivalirudin versus Heparin in Acute Myocardial Infarction: Rationale and MethodologyBehnood Bikdeli, Thomas McAndrew, Aaron Crowley, et al.
JAMA|October 24, 2023
Traditional Chinese Medicine Compound (Tongxinluo) and Clinical Outcomes of Patients With Acute Myocardial Infarction: The CTS-AMI Randomized Clinical TrialYuejin Yang, Xiangdong Li, Guihao Chen, et al.
JACC. Asia|February 19, 2024
Effects of Dapagliflozin in Patients in Asia: A Post Hoc Subgroup Analysis From the DELIVER TrialXiaowen Wang, Carolyn S P Lam, Muthiah Vaduganathan, et al.
Journal of the American College of Cardiology|February 11, 2026
Sirolimus-Eluting Iron Bioresorbable Scaffolds vs Everolimus-Eluting Stents for Percutaneous Coronary Intervention: A Randomized Trial (IRONMAN II)Runlin Gao, Lei Song, Guosheng Fu, et al.
Scientific Reports|September 15, 2016
Six Versus Twelve Months Clopidogrel Therapy After Drug-Eluting Stenting in Patients With Acute Coronary Syndrome: An ISAR-SAFE Study Subgroup AnalysisRaphaela Lohaus, Jonathan Michel, Katharina Mayer, et al.
Pageof 41